Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, October 22, 2025 -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2025, and provided an update on its clinical pipe ...